SRRK Scholar Rock Holding Corporatio
$55.41▼ -0.47%
Healthcare
Other
After hours
$61.97▲ +11.84%
Sep 11, 7:59 PM ET
Volume 921.7K
Avg Volume (10D) 1.03M
Key Metrics & Fundamentals
Market Cap
$6.75B
P/E Ratio
–
Div Yield
–%
52W Range
27.07 - 61.76
% vs 50 MA
3.48%
% vs 200 MA
15.31%
RSI-14
51.2
MACD Histogram
-0.4000
Beta (1Y vs SPY)
0.94
Free Cash Flow
-$70.31M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$105.08M
COGS
–
Operating Exp
$108.90M
Operating Income
-$108.90M
EBIT
-$108.90M
Pretax Income
-$109.90M
Net Income
-$109.90M
EPS (Diluted)
-0.84
Price & Volume History
Loading chart…
Recent News
Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours
Stocktwits · Sep 11, 2026 11:31 PM
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
Business Wire · Sep 11, 2026 10:25 PM
Scholar Rock Gets FDA Fast Track, Orphan Drug Designations for Muscular Disorder Drug
MT Newswires · Sep 2, 2026 12:23 PM
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
Business Wire · Sep 2, 2026 12:00 PM
Scholar Rock to Present at Upcoming Investor Conferences
Business Wire · Aug 27, 2026 12:00 PM
Scholar Rock (SRRK) Stock Looks Stretched On Book Value But Strong On Returns
Simply Wall St. · Aug 22, 2026 2:07 PM
Is Scholar Rock Holding (SRRK) Fairly Valued On Its Apitegromab Regulatory Progress?
Simply Wall St. · Aug 22, 2026 11:09 AM
Scholar Rock (SRRK) Streamlines Apitegromab Filings After Catalent Shift Is Regulatory Strategy De-Risking The Story?
Simply Wall St. · Aug 22, 2026 8:09 AM
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing
Stocktwits · Aug 21, 2026 9:50 PM
Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says
MT Newswires · Aug 21, 2026 7:03 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SRRK's money flow as a full page
Social Sentiment
Avg +0.78 · 12 posts
TradeDDSRRK - School House Rock
r/wallstreetbets · Jul 7, 2026
Strong bullish sentiment with technical analysis and speculation on future growth.
positive
+0.80
DDNewsDiscussionScholar Rock (SRRK)
r/wallstreetbets · Jul 1, 2026
The author strongly advocates for SRRK based on clinical trial data and potential partnerships.
positive
+0.80
NewsDiscussionDDScholar Rock (SRRK)
r/wallstreetbets · Jul 1, 2026
The author highlights positive trial results, FDA resubmission, potential acquisition by Novo Nordisk, and a partnership – all indicating strong sentiment.
positive
+0.80
DDNewsDiscussionHow Scholar Rock’s (SRRK) FDA Progress and Apitegromab Plans Have Changed Its Investment Story
r/wallstreetbets · Nov 14, 2025
The post is centered on SRRK and expresses a desire for a better outcome regarding previous content.
positive
+0.80
NewsDiscussionThe dip in Scholar Holding (SRRK)
r/wallstreetbets · Oct 20, 2025
The discussion focuses on positive aspects of the company's drug development and FDA approvals.
positive
+0.70
Page 1 of 3 (12 total)
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.